GYRE — Gyre Therapeutics Cashflow Statement

0.000.00%

Last trade - 00:00

HealthcareSpeculativeMid CapNeutral

Annual cashflow statement for Gyre Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	10-K	10-K	10-K	10-K	10-K
Standards:	USG	USG	USG	USG	USG
Status:	Final	Final	Final	Final	Final
Net Income/Starting Line	-56.2	-87.9	-8.24	-85.5	17.9
Depreciation
Deferred Taxes
Non-Cash Items	3.63	3.4	-20.1	105	-5.35
Unusual Items
Purchased R&D
Equity in Net Earnings/Losses
Other Non-Cash Items
Changes in Working Capital	-2.57	0.483	-4.95	6.83	-16.7
Change in Accounts Receivable
Change in Inventories
Change in Prepaid Expenses
Change in Accounts Payable
Change in Accrued Expenses
Change in Taxes Payable
Change in Other Liabilities
Net Change in Other Assets & Liabilities
Cash from Operating Activities	-55	-83.8	-33.1	25.9	-3.64
Capital Expenditures	-0.267	-0.839	0	-8.59	-3.13
Purchase of Fixed Assets
Purchase / Acquisition of Intangibles
Other Investing Cash Flow Items	9.93	49	55.4	-11.2	-16.8
Acquisition of Business
Sale of Fixed Assets
Sale/Maturity of Investment
Purchase of Investments
Other Investing Cash Flow
Cash from Investing Activities	9.66	48.2	55.4	-19.8	-19.9
Financing Cash Flow Items	—	—	—	—	-0.536
Other Financing Cash Flow
Total Cash Dividends Paid
Net Issuance / Retirement of Stock
Cash from Financing Activities	60.4	49.6	-45	2.5	2.1
Foreign Exchange Effects
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash	15	14	-22.7	8.33	-21.7